Striato-cortical connections in Parkinson’s and Alzheimer’s diseases: relation to cognition
Objective: To evaluate resting-state striato-cortical connectivity in PD and mild cognitive impairment due to Alzheimer's disease (AD-MCI) and assess their relation to cognitive outcomes. We…Marked occipital hypometabolism on FDG-PET in patients with idiopathic RBD may predict Parkinson’s disease
Objective: In the present study, we tried to elucidate if the occipital hypometabolism detected by [(18) F]-fluoro-d-glucose (FDG) positron emission tomography (PET) scan in patients with idiopathic…Utility of DaTscan Imaging in Differentiating Drug Induced Parkinsonism from IPD and Other Forms of Parkinsonism
Objective: To determine clinical correlates which differentiate drug induced Parkinsonism (DIP) from IPD and other forms of Parkinsonism using DaT-SPECT imaging. Background: DaT-SPECT imaging is…Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease – on behalf of Critical Path for Parkinson’s (CPP) Consortium
Objective: A key goal of the Critical Path for Parkinson’s Consortium (CPP) is to qualify, with regulatory agencies, drug development tools for use in PD…In vivo mapping of nigro-striatal dopamine transporter (DAT) availability in early Parkinson´s disease patients using [18F]FE-PE2I and high-resolution positron emission tomography.
Objective: The objective of the present work was to evaluate in vivo with high resolution positron emission tomography (PET), the relative loss of the dopamine…Non-motor symptoms in Parkinson’s disease and putamen dopamine transporter uptake (DaTscan) uptake: a survey of 85 patients
Objective: We addressed association between 30 non-motor symptoms (NMS) (using the validated Parkinson’s disease (PD) NMS Scale (NMSS)), and DaTscan putamen uptake ratios as part…Clinical characteristics of scan without evidence of dopaminergic deficits (SWEDDs) in Japan.
Objective: To examine the clinical characteristics of SWEDDs and to compare to that of Parkinson’s disease (PD). Background: Patients with SWEDDs are defined as clinically…Brain PET metabolic substrate of Impulse Control Disorders in Parkinson’s Disease
Objective: The aim of this study was to describe the cerebral metabolic PET substrate and related connectivity changes in Parkinson's disease patients with impulse control…Longitudinal Cortical Thickness Changes in GBA-Positive Relative to GBA-negative Parkinson’s Disease Patients with Hemiparkinsonism
Objective: This study investigated the longitudinal changes of the cortical grey matter in Parkinson’s disease (PD) patients with hemiparkinsonism, with (GBA-positive) and without (GBA-negative) glucocerebrosidase…Cognitive changes and cortical thinning evolution of parkinson’s disease patients: 4-year-follow up.
Objective: The aim of the study was to investigate differences in the progression of cognitive decline and cortical thinning evolution in Parkinson’s disease (PD) patients…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.